AUS
NZ
UK
CA
USA
IND
Little Green Pharma Ltd (ASX:LGP) has applied for the quotation of 4 million fully paid ordinary shares on the Australian Securities Exchange following the conversion of employee performance rights and share rights. The company revealed that 3 million shares were allocated to former Director Fleta Solomon upon converting performance rights, with an additional 1 million shares issued to the same individual through share rights conversion, both effective on 27 July 2026. These share issuances mark a notable change in the company’s capital structure and highlight the vesting of long-term incentive arrangements for a past leadership team member.
Key Highlights
- Little Green Pharma Ltd (LGP), an ASX-listed pharmaceutical firm, has applied for quotation of shares following conversions of convertible securities.
- A total of 4 million ordinary fully paid shares were issued on 27 July 2026 through two separate conversions.
- 3 million shares were issued to ex-Director Fleta Solomon via performance rights (LGPAT class), and 1 million shares through share rights (LGPAS class) conversion.
- Post-conversion, the company's total quoted ordinary share capital stands at 827,978,691 shares, with various unquoted options and share rights still outstanding.
- The company holds unquoted options expiring in July 2027 and July 2028, along with approximately 204.5 million unquoted share rights.
Overview of Little Green Pharma’s Operations and ASX Listing
Little Green Pharma Ltd operates as a pharmaceutical company listed on the ASX under the ticker LGP. Registered in Australia with ACN 615586215, the company complies with ASX Listing Rules, including continuous disclosure and the quotation of new securities. The recent issuance of shares through the conversion of employee performance and share rights reflects the company’s use of long-term incentive programs to align employee interests with shareholder value, a common practice among ASX-listed entities.
Operating within the capital-intensive pharmaceutical sector, Little Green Pharma employs performance rights and share rights as part of executive and senior staff remuneration packages. These instruments typically vest upon meeting specific performance targets or service durations. Their conversion into ordinary shares signifies the fulfillment of vesting conditions and underscores the company’s strategy to incentivize key personnel.
Details of 3 Million Performance Rights Conversion to Ex-Director Fleta Solomon
On 27 July 2026, Little Green Pharma issued 3 million fully paid ordinary shares to former Director Fleta Solomon following the conversion of performance rights categorized under ASX code LGPAT. This conversion fully extinguished the LGPAT class performance rights, with shares intended for ASX quotation pending approval. The shares were issued without cash consideration and rank equally with existing LGP ordinary shares from the issue date. The timing indicates that vesting conditions tied to these performance rights were met on the conversion date, enabling Solomon to exercise her conversion rights.
Issuance of 1 Million Shares from Share Rights Conversion and Capital Structure Impact
Additionally, 1 million fully paid ordinary shares were issued to ex-Director Fleta Solomon on 27 July 2026 following the conversion of share rights classified under ASX code LGPAS. This separate incentive instrument also converted without cash payment on the same date as the performance rights, suggesting coordinated vesting. Post-conversion, the LGPAS share rights outstanding decreased from 3 million to 2 million. Although Solomon is no longer a key management personnel (KMP), the application indicates KMP holdings, possibly reflecting original grant status or associates.
Post-Conversion Issued Capital Overview
With the approval and quotation of these 4 million shares, Little Green Pharma’s total issued ordinary share capital increases to 827,978,691 shares. This figure encompasses all previously issued shares plus the newly converted shares, providing a comprehensive view of the company’s equity post-conversion. The company did not disclose the pre-conversion share count, so the precise percentage increase remains unspecified.
Beyond ordinary shares, the company holds 14.4 million unquoted options split evenly between two series: 7.2 million expiring 31 July 2028 at an exercise price of $0.18, and 7.2 million expiring 31 July 2027 at $0.138. Additionally, approximately 204.5 million unquoted share rights remain outstanding across LGPAA and LGPAS classes, representing potential future dilution if exercised.
Employee Incentive Scheme and Vesting Mechanisms
The conversion of performance and share rights to Fleta Solomon illustrates Little Green Pharma’s employee incentive framework, which aligns employee and shareholder interests through remuneration linked to performance or tenure. The simultaneous vesting of 3 million performance rights and 1 million share rights on 27 July 2026 indicates satisfaction of associated conditions. Specific vesting criteria, original grant dates, or valuation details were not disclosed, prompting investors to consult company remuneration disclosures for further insights.
No Cash Consideration and Accounting Implications
The share conversions involved no cash consideration, consistent with typical treatment of such instruments where vesting satisfies conversion rights without additional payment. This issuance does not raise capital but reflects fulfillment of remuneration obligations, reshaping the capital structure rather than funding operations. The announcement does not specify any escrow or trading restrictions applicable post-quotation.
Remaining Unquoted Securities and Potential Dilution Risks
Following these conversions, Little Green Pharma retains a substantial portfolio of unquoted convertible securities, including approximately 204.5 million share rights and 14.4 million options. These instruments could significantly dilute existing shareholders if exercised or converted. The options are split between two series with varying expiry dates and exercise prices, potentially offering in-the-money opportunities depending on share price movements. Investors should monitor these securities for their impact on future capital structure and ownership stakes.
Compliance with ASX Listing Rules and Disclosure
The company’s application for quotation complies with ASX Listing Rules governing securities issued from convertible instruments. The submitted Appendix 2A includes all required disclosures such as issue details, conversion terms, and updated issued capital. The newly issued shares rank equally with existing LGP ordinary shares, ensuring consistent rights and privileges across shareholders. This adherence to regulatory requirements reflects Little Green Pharma’s commitment to transparency and governance as a listed entity.
Strategic Context of Leadership Transition and Incentive Vesting
The conversion of incentives to ex-Director Fleta Solomon coincides with her departure from the board, with vesting conditions likely established at the time of grant extending beyond her tenure. This approach aligns with corporate governance practices that use long-term incentives to retain and reward executives even after leadership transitions. The 4 million shares awarded underscore Solomon’s significant role within the company’s leadership during her tenure.
Impact on Share Register and Shareholder Base
The issuance of 4 million shares to Fleta Solomon will update the company’s shareholder register, representing approximately 0.48% of the total issued ordinary share capital of 827,978,691 shares post-conversion. This stake may trigger substantial shareholder notification requirements under the Corporations Act 2001 (Cth), though no such disclosures have been reported. Investors should watch for any substantial holding notices related to Solomon’s shareholding as part of ongoing market transparency.
